AKT1 and prostate carcinoma: In addition to excellent kinetic solubility (> 190 μM), compound 2 produced a marked decrease in phosphorylation of the AKT substrate pGSK3β in PC3 prostate cancer cells, with a potency improvement of ca. 30-fold when compared with the des-N-methyl analogue 1.